|
1
|
Davis RJ: Signal transduction by the JNK
group of MAP kinases. Cell. 103:239–252. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kralova J, Sheely JI, Liss AS and Bose HR
Jr: ERK and JNK activation is essential for oncogenic
transformation by v-Rel. Oncogene. 29:6267–6279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Binétruy B, Smeal T and Karin M: Ha-Ras
augments c-Jun activity and stimulates phosphorylation of its
activation domain. Nature. 351:122–127. 1991.PubMed/NCBI
|
|
4
|
Smeal T, Binétruy B, Mercola DA, Birrer M
and Karin M: Oncogenic and transcriptional cooperation with Ha-Ras
requires phosphorylation of c-Jun on serines 63 and 73. Nature.
354:494–496. 1991. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mechta F, Lallemand D, Pfarr CM and Yaniv
M: Transformation by ras modifies AP1 composition and activity.
Oncogene. 14:837–847. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Minden A and Karin M: Regulation and
function of the JNK subgroup of MAP kinases. Biochim Biophys Acta.
1333:F85–F104. 1997.PubMed/NCBI
|
|
7
|
Verheij M, Ruiter GA, Zerp SF, van
Blitterswijk WJ, Fuks Z, Haimovitz-Friedman A and Bartelink H: The
role of the stress-activated protein kinase (SAPK/JNK) signaling
pathway in radiation-induced apoptosis. Radiother Oncol.
47:225–232. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paul A, Wilson S, Belham CM, Robinson CJ,
Scott PH, Gould GW and Plevin R: Stress-activated protein kinases:
activation, regulation and function. Cell Signal. 9:403–410. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gupta S, Barrett T, Whitmarsh AJ, Cavanagh
J, Sluss HK, Dérijard B and Davis RJ: Selective interaction of JNK
protein kinase isoforms with transcription factors. EMBO J.
15:2760–2770. 1996.PubMed/NCBI
|
|
10
|
Adler V, Fuchs SY, Kim J, Kraft A, King
MP, Pelling J and Ronai Z: jun-NH2-terminal kinase
activation mediated by UV-induced DNA lesions in melanoma and
fibroblast cells. Cell Growth Differ. 6:1437–1446. 1995.
|
|
11
|
Amdjadi K and Sefton BM: Ultraviolet
light-induced stimulation of the JNK mitogen-activated protein
kinase in the absence of src family tyrosine kinase activation. J
Biol Chem. 275:22520–22525. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Potapova O, Haghighi A, Bost F, Liu C,
Birrer MJ, Gjerset R and Mercola D: The Jun kinase/stress-activated
protein kinase pathway functions to regulate DNA repair and
inhibition of the pathway sensitizes tumor cells to cisplatin. J
Biol Chem. 272:14041–14044. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saleem A, Datta R, Yuan ZM, Kharbanda S
and Kufe D: Involvement of stress-activated protein kinase in the
cellular response to 1-β-D-arabinofuranosylcytosine and other
DNA-damaging agents. Cell Growth Differ. 6:1651–1658. 1995.
|
|
14
|
Osborn MT and Chambers TC: Role of the
stress-activated/c-Jun NH2-terminal protein kinase
pathway in the cellular response to adriamycin and other
chemotherapeutic drugs. J Biol Chem. 271:30950–30955.
1996.PubMed/NCBI
|
|
15
|
Hashimoto A, Kurosaki M, Gotoh N, Shibuya
M and Kurosaki T: Shc regulates epidermal growth factor-induced
activation of the JNK signaling pathway. J Biol Chem.
274:20139–20143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bost F, McKay R, Dean N and Mercola D: The
JUN kinase/stress-activated protein kinase pathway is required for
epidermal growth factor stimulation of growth of human A549 lung
carcinoma cells. J Biol Chem. 272:33422–33429. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang SA, Lee ES, Yoon HY, Randazzo PA and
Lee ST: PTK6 inhibits down-regulation of EGF receptor through
phosphorylation of ARAP1. J Biol Chem. 285:26013–26021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van Dam H, Wilhelm D, Herr I, Steffen A,
Herrlich P and Angel P: ATF-2 is preferentially activated by
stress-activated protein kinases to mediate c-jun induction in
response to genotoxic agents. EMBO J. 14:1798–1811. 1995.PubMed/NCBI
|
|
19
|
Pulverer BJ, Kyriakis JM, Avruch J,
Nikolakaki E and Woodgett JR: Phosphorylation of c-jun mediated by
MAP kinases. Nature. 353:670–674. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tanabe M, Izumi H, Ise T, Higuchi S,
Yamori T, Yasumoto K and Kohno K: Activating transcription factor 4
increases the cisplatin resistance of human cancer cell lines.
Cancer Res. 63:8592–8595. 2003.PubMed/NCBI
|
|
21
|
Crul M, Schellens JH, Beijnen JH and
Maliepaard M: Cisplatin resistance and DNA repair. Cancer Treat
Rev. 23:341–366. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Parra E and Ferreira J: Knockdown of the
c-Jun-N-terminal kinase expression by siRNA inhibits MCF-7 breast
carcinoma cell line growth. Oncol Rep. 24:1339–1345. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsuiki H, Tnani M, Okamoto I, Kenyon LC,
Emlet DR, Holgado-Madruga M, Lanham IS, et al: Constitutively
active forms of c-Jun NH2-terminal kinase are expressed
in primary glial tumors. Cancer Res. 63:250–255. 2003.PubMed/NCBI
|
|
24
|
Vivas-Mejia P, Benito JM, Fernandez A, Han
HD, Mangala L, Rodriguez-Aguayo C, et al:
c-Jun-NH2-kinase-1 inhibition leads to antitumor
activity in ovarian cancer. Clin Cancer Res. 16:184–194. 2010.
|
|
25
|
Lovejoy KS, Todd RC, Zhang S, McCormick
MS, D’Aquino JA, Reardon JT, Sancar A, Giacomini KM and Lippard SJ:
cis-Diammine (pyridine)chloroplatinum(II), a monofunctional
platinum(II) antitumor agent: uptake, structure, function, and
prospects. Proc Natl Acad Sci USA. 105:8902–8907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Levresse V, Marek L, Blumberg D and
Heasley LE: Regulation of platinum-compound cytotoxicity by the
c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell
lung cancer cells. Mol Pharmacol. 62:689–697. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Helbig L, Damrot J, Hülsenbeck J, Köberle
B, Brozovic A, Osmak M, Fiket Z, Kaina B and Fritz G: Late
activation of stress-activated protein kinases/c-Jun N-terminal
kinases triggered by cisplatin-induced DNA damage in
repair-defective cells. J Biol Chem. 286:12991–13001. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fritz G and Kaina B: Late activation of
stress kinases (SAPK/JNK) by genotoxins requires the DNA repair
proteins DNA-PKcs and CSB. Mol Biol Cell. 17:851–861. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brozovic A, Fritz G, Christmann M,
Zisowsky J, Jaehde U, Osmak M and Kaina B: Long-term activation of
SAPK/JNK, p38 kinase and fas-L expression by cisplatin is
attenuated in human carcinoma cells that acquired drug resistance.
Int J Cancer. 112:974–985. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hayakawa J, Depatie C, Ohmichi M and
Mercola D: The activation of c-Jun NH2-terminal kinase
(JNK) by DNA-damaging agents serves to promote drug resistance via
activating transcription factor 2 (ATF2)-dependent enhanced DNA
repair. J Biol Chem. 278:20582–20592. 2003.
|
|
31
|
Smeal T, Binetruy B, Mercola D,
Grover-Bardwick A, Heidecker G, Rapp UR and Karin M:
Oncoprotein-mediated signalling cascade stimulates c-Jun activity
by phosphorylation of serines 63 and 73. Mol Cell Biol.
12:3507–3513. 1992.PubMed/NCBI
|
|
32
|
Boyle WJ, Smeal T, Defize LH, Angel P,
Woodgett JR, Karin M and Hunter T: Activation of protein kinase C
decreases phosphorylation of c-Jun at sites that negatively
regulate its DNA-binding activity. Cell. 64:573–584. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Parra E, Ortega A and Saenz L:
Down-regulation of Egr-1 by siRNA inhibits growth of human prostate
carcinoma cell line PC-3. Oncol Rep. 22:1513–1518. 2009.PubMed/NCBI
|
|
34
|
Parra E, Ferreira F and Saenz L:
Inhibition of Egr-1 by siRNA in prostate carcinoma cell lines is
associated with decreased expression of AP-1 and NF-κB. Int J Mol
Med. 28:847–853. 2011.PubMed/NCBI
|
|
35
|
Parra E, Ferreira J and Ortega A:
Overexpression of EGR-1 modulates the activity of NF-κB and AP-1 in
prostate carcinoma PC-3 and LNCaP cell lines. Int J Oncol.
39:345–352. 2011.PubMed/NCBI
|
|
36
|
Inostroza J, Sáenz L, Calaf G, Cabello G
and Parra E: Role of the phosphatase PP4 in the activation of JNK-1
in prostate carcinoma cell lines PC-3 and LNCaP resulting in
increased AP-1 and EGR-1 activity. Biol Res. 38:163–178. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu JJ, Li Q and Reed E: Comparison of two
human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are
equally resistant to platinum, but differ at codon 118 of the ERCC1
gene. Int J Oncol. 16:555–560. 2000.PubMed/NCBI
|
|
38
|
Ma FY, Flanc RS, Tesch GH, Han Y, Atkins
RC, Bennett BL, Friedman GC, Fan JH and Nikolic-Paterson DJ: A
pathogenic role for c-Jun amino-terminal kinase signaling in renal
fibrosis and tubular cell apoptosis. J Am Soc Nephrol. 18:472–484.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vivanco I, Palaskas N, Tran C, Finn SP,
Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, et al:
Identification of the JNK signaling pathway as a functional target
of the tumor suppressor PTEN. Cancer Cell. 11:555–569. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cellurale C, Girnius N, Jiang F,
Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM and Davis RJ: Role
of JNK in mammary gland development and breast cancer. Cancer Res.
72:472–481. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Burgess GS, Williamson EA, Cripe LD,
Litz-Jackson S, Bhatt JA, Stanley K, Stewart MJ, Kraft AS,
Nakshatri H and Boswell HS: Regulation of the c-jun gene in p210
BCR-ABL transformed cells corresponds with activity of JNK, the
c-jun N-terminal kinase. Blood. 92:2450–2460. 1998.PubMed/NCBI
|
|
42
|
Raitano AB, Halpern JR, Hambuch TM and
Sawyers CL: The Bcr-Abl leukemia oncogene activates Jun kinase and
requires Jun for transformation. Proc Natl Acad Sci USA.
92:11746–11750. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu J, Minemoto Y and Lin A: c-Jun
N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for
tumor necrosis factor alpha-induced c-Jun kinase activation and
apoptosis. Mol Cell Biol. 24:10844–10856. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hayakawa J, Mittal S, Wang Y, Korkmaz KS,
Adamson E, English C, Ohmichi M, McClelland M and Mercola D:
Identification of promoters bound by c-Jun/ATF2 during rapid
large-scale gene activation following genotoxic stress. Mol Cell.
16:521–535. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Halazonetis TD, Georgopoulos K, Greenberg
ME and Leder P: c-Jun dimerizes with itself and with c-Fos, forming
complexes of different DNA binding affinities. Cell. 55:917–924.
1988. View Article : Google Scholar : PubMed/NCBI
|
